ccr2 antagonist incb3344 (Selleck Chemicals)
Structured Review

Ccr2 Antagonist Incb3344, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ccr2 antagonist incb3344/product/Selleck Chemicals
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2 + Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma"
Article Title: Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2 + Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Journal: Cancer Research
doi: 10.1158/0008-5472.CAN-22-3140
Figure Legend Snippet: MCs correlate with the infiltration of CCR2 + CTLs. A, Left, heat map showing the Pearson correlation of the immune cell population by FCM. Number representing the Pearson correlation index. Right, the transcriptional correlation of the transcriptional levels of MC marker (TPSAB1) and T-cell markers (CD4, CD8A, and FOXP3). B, The expression of chemokines in MCs from nLung, gLUAD, and sLUAD samples. The shaded areas represent the upper quantile and lower quantile. C, The secretion of CCL2, CCL4, CCL5, and CXCL8 by MCs detected by Luminex. Ctr, unstimulated MCs; solid, stimulated MCs from solid LUAD; GGO, stimulated MCs from GGO. D, Representative flow plots showing CCR2 + CTLs gating (left) and proportion of CCR2 + CTLs among tumor-infiltrating CTLs (right). FMO, fluorescence minus one. n = 36 (Mann–Whitney). E, Scatterplot showing the Pearson correlation of the proportion of CCR2 + CTLs (divided by the total CTL number) and MCs (divided by the total CD45 + cells) by FCM analysis ( n = 10). F, Three-plex staining panel showing the spatial distribution of CCR2 + CTLs and MCs. G, Spatial analysis of the relationship between MCs and CTLs. Left, depiction of methodology for spatial analyses performed. The number of CTLs close to per MCs. H, The migration rate of CTLs (the ratio of migrated CTLs to total CTLs) in the transwell assay ( n = 6, paired t test). Blank group, medium only; TS group, tumor supernatants; Usti-MC group, nonstimulated MCs; and Sti-MC group, stimulated MCs. I, The migration rate of CTLs (the ratio of migrated CTLs to total CTLs) in the migration blocking assay ( n = 4, paired t test). CCR2 T − , CCR2 − CTLs; CCR2 T + , CCR2 + CTLs. *, P < 0.05; **, P < 0.01; ns, nonsignificant.
Techniques Used: Marker, Expressing, Luminex, Fluorescence, MANN-WHITNEY, Staining, Migration, Transwell Assay, Blocking Assay
Figure Legend Snippet: Characterization of LUAD-infiltrating CCR2 + CTLs. A, Bar plot showing the expression of costimulatory molecules. The x -axis value represents the FC of the expression in costimulation molecules on CCR2 − CTLs or CCR2 + CTLs compared with bulk CTLs ( n = 4). B, Box plot showing the expression of coinhibitory molecules ( n = 4). C, Frequency of TRM + (CD103, top; CD49a, middle; CD69, bottom) CCR2 − CTLs or CCR2 + CTLs. Representative flow plots (left) and summary (right) of four independent experiments (paired t test). D, Frequency of granzyme K expressing CCR2 − CTLs or CCR2 + CTLs ( n = 4; paired t test). E, Frequency of cytotoxic molecule–secreted CCR2 − CTLs or CCR2 + CTLs ( n = 6; paired t test). F, Left, representative flow plots showing the apoptosis of cocultured GFP-A549 cell line. Right, proportion of surviving target cells ( n = 4; Wilcoxon test). G, Representative example of LUAD section stained by mIF with anti-CCR2 (red), CD8 (green), and tryptase (blue) antibodies. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Techniques Used: Expressing, Staining
Figure Legend Snippet: MCs correlated with therapeutic response to TKI therapy but not chemotherapy. A, Clinic relevance of CCL2 + MCs (Mann–Whitney). B, Clinic relevance of CCR2 + CTLs (two-tailed unpaired t test). C, Oncogene mutation relevance of CCL2 + MCs or CCR2 + CTLs ( χ 2 test). D, The prognostic value of CCL2 + MCs–CCR2 + CTLs in surgically resected LUAD. P values were determined by the log-rank test. E, Nomogram showing independent prognostic factors for survival in surgically resected LUAD by Cox proportional hazard analyses (*, independent prognostic factors). F, The prognostic value of CCL2 + MCs in patients with LUAD treated with chemotherapy. P values were determined by the log-rank test. G, The correlation of risk of recurrence after chemotherapy and CCL2 + MCs. The P value was determined by the χ 2 test. H, MC quantification as a proportion of immune cells (Mann–Whitney; n = 15 for the TN group; n = 14 for the RD group; and n = 20 for the PD group). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, nonsignificant.
Techniques Used: Clinical Proteomics, MANN-WHITNEY, Two Tailed Test, Mutagenesis


